Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease
Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease
复制标题
DOI：
10.1016/j.amjcard.2008.11.018
复制
发表时间：
2009-02-02
影响因子：
2.8
通讯作者：
Bhatt, Deepak L.
中科院分区：
文献类型：
--
作者：
Bhatt, Deepak L.
抗血小板治疗是冠状动脉疾病表现谱中的一种重要治疗方式。阿司匹林在一级预防中的作用继续得到完善。尽管阿司匹林或氯吡格雷单药治疗已被证实可用于二级预防，但对于高危患者，如急性冠脉综合征或需要经皮冠状动脉介入治疗的患者，双重抗血小板治疗似乎最有益。关于双联抗血小板治疗的适当持续时间仍然存在问题，特别是在既往有缺血事件或接受第一代药物洗脱支架的患者中，间接证据表明持续时间较长更好。(C)2009年由Elsevier Inc.出版(Am J Cardiol 2009;103[增刊]：11 A-19 A）
Antiplatelet therapy is an important treatment modality across the spectrum of coronary artery disease manifestations. The role of aspirin in primary prevention continues to be refined. Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial. Questions remain about the appropriate duration of dual antiplatelet therapy, especially in patients with prior ischemic events or in those receiving first-generation drug-eluting stents, with indirect evidence suggesting longer durations are better. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;103[suppl]:11A-19A)